Результати пошуку - Seock‐Ah Im

Уточнити результати
  1. 1
    PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

    PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation за авторством Ahrum Min, Seock Ah Im

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor

    HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor за авторством Hyeyeon Chang, Yong‐Won Shin, Bhumsuk Keam, Miso Kim, Seock‐Ah Im, Soon‐Tae Lee

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

    Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer за авторством José Baselga, Javier Cortés, Seock‐Ah Im, Emma Clark, Graham Ross, Astrid Kiermaier, Sandra M. Swain

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies

    The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies за авторством Javier Cortés, Seock‐Ah Im, Esther Holgado, José Manuel Pérez-García, Peter Schmid, Mariana Chávez‐MacGregor

    Опубліковано 2017
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  5. 5
    Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer

    Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer за авторством Sun Kyung Baek, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Опубліковано 2011
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?

    BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs? за авторством Peter Dubsky, Christian Jackisch, Seock‐Ah Im, Kelly K. Hunt, Chien‐Feng Li, Sheila Unger, Shani Paluch–Shimon

    Опубліковано 2024
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  7. 7
    Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin

    Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin за авторством Sun Kim, H.S. Kim, Yu Kim, Do Oh, Seock‐Ah Im, Dongsoon Lee, Hyun-Soon Jong, Tae‐You Kim, Yung‐Jue Bang

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Antibiotic use during the last days of life in cancer patients

    Antibiotic use during the last days of life in cancer patients за авторством Dong Yoon Oh, J. Kim, Dong‐Wan Kim, Seock‐Ah Im, T.Y. KIM, D. S. Heo, Y-J. Bang, N.K. KIM

    Опубліковано 2006
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

    Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the... за авторством Sandra M. Swain, Young‐Hyuck Im, Seock‐Ah Im, Valorie F. Chan, David Miles, Adam Knott, Emma Clark, Graham Ross, José Baselga

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index

    Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index за авторством Younak Choi, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy

    The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy за авторством Younak Choi, Tae-Yong Kim, Do‐Youn Oh, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

    Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells за авторством Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Hyung-Seok Hur, Do Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Tae‐You Kim

    Опубліковано 2009
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

    Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer:... за авторством Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> trial

    Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> tri... за авторством Elżbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conté, Seock‐Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark E. Robson, Nadine Tung

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer

    Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer за авторством Chan‐Young Ock, Do‐Youn Oh, Joongyub Lee, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer

    Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract... за авторством Kyoung-Min Cho, Hyunkyung Park, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Опубліковано 2016
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

    The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer за авторством Jiyoung Rhee, Sae‐Won Han, Do‐Youn Oh, Jee Hyun Kim, Seock‐Ah Im, Wonshik Han, In Ae Park, Dong‐Young Noh, Yung‐Jue Bang, Tae‐You Kim

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer

    Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer за авторством Dong-Hyeon Ha, Ahrum Min, Seongyeong Kim, Hyemin Jang, So Hyeon Kim, Hee Jun Kim, Han Suk Ryu, Ja‐Lok Ku, Kyung-Hun Lee, Seock‐Ah Im

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology

    The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology за авторством Kelly A. Hirko, Gabrielle B. Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey Cutress, Ellen Copson, Dae‐Won Lee, Kyung-Hun Lee, Seock‐Ah Im, Yeon Hee Park

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    <i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

    <i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis за авторством Ming Yin, Jingrong Yan, Eva Martinez‐Balibrea, Francesco Graziano, Heinz‐Josef Lenz, Hyo-Jin Kim, Jacques Robert, Seock‐Ah Im, Wei-Shu Wang, Marie-Christine Etienne-Grimaldi, Qingyi Wei

    Опубліковано 2011
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: